DelveInsight’s, “Herpes labialis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Herpes labialis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Herpes labialisUnderstanding
Herpes labialis: Overview
Herpes labialis or oral herpes is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus, a common and highly contagious virus that infects most people in the U.S by time they reach the age of 20. There are three stages of infection that occur in oral herpes, which include the primary infection, the latency period and recurrence. During the initial stage of infection, the virus enters the skin or mucosal membrane, where it then reproduces. Blisters and other symptoms such as fever may develop, although the virus sometimes does not cause any symptoms.

"Herpes labialis- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes labialis pipeline landscape is provided which includes the disease overview and Herpes labialis treatment guidelines. The assessment part of the report embraces, in depth Herpes labialis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes labial collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Herpes labialisR&D. The therapies under development are focused on novel approaches to treat/improve Herpes labialis.

Herpes labialisEmerging Drugs Chapters
This segment of the Herpes labialisreport encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Herpes labialis Emerging Drugs
• Pritelivir (AIC316): AiCuris
Pritelivir (AIC316) is a highly potent inhibitor of herpes simplex virus (HSV) replication. Pritelivir belongs to a new chemical class and acts via a novel mechanism of action (inhibition of the viral helicase-primase enzyme complex). Due to this novel mechanism of action, and in contrast to the currently used nucleoside analogues, pritelivir does not require activation by viral enzymes and can thus protect uninfected cells. Pritelivir is active against herpes virus strains and retains activity against viruses which have become resistant to current standard drugs. In Phase 2 clinical trials, Pritelivir has shown superiority over the market standard treatment valacyclovir. Pritelivir is currently in a Phase 2 clinical trial for immunocompromised patients with acyclovir-resistant infection. The drug is in phase 2 of clinical trials for the treatment of Herpes labialis.

• BTL-TML : Beech Tree Labs
In preclinical studies, BTL-TML interfered with the translation of proteins involved in viral replication and the structural integrity of infected cells (tubulin synthesis). In addition, genomic studies showed that BTL-TML downregulates several pro-inflammatory cytokine genes while up-regulating anti-inflammatory genes. Together, these effects could potentially limit the virus’s ability to reproduce, spread and cause overactive immune responses (cytokine storms) associated with poor outcomes. The drug is in phase 2 of clinical trials for the treatment of Herpes labialis.
Further product details are provided in the report……..

Herpes labialis: Therapeutic Assessment
This segment of the report provides insights about the different Herpes labialis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Herpes labialis
There are approx. 4+ key companies which are developing the therapies for Herpes labialis. The companies which have their Herpes labialis drug candidates in the most advanced stage, i.e. phase II include, AiCuris.

• Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Herpes labialis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Herpes labialis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Herpes labialis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes labialis drugs.

Herpes labialis Report Insights
• Herpes labialis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Herpes labialis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Herpes labialis drugs?
• How many Herpes labialis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Herpes labialis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Herpes labialis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Herpes labialis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• AiCuris
• Beech Tree Labs
• Laboratoire Boreaderme Inc.

Key Products
• Pritelivir (AIC316)
• BTL-TML
• BOR15001L7